Jeanne‐Marie Devaster

Author

Also Known As

J M Devaster, J. M. Devaster, J.-M. Devaster, J.M. Devaster, JEANNE-MARIE DEVASTER, Jeanne-Marie Devaster, Jeanne‐Marie Devaster, Kristoffer Ostridge, N. A. Coombs, Sonia Mesia-Vela

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (Belgium)Ghent University Hospital University of Southampton GGD Rotterdam-Rijnmond GlaxoSmithKline (United States)

About

Jeanne‐Marie Devaster is an author at GlaxoSmithKline (Belgium) specializing in medicine, vaccination, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	923
2	Immunology	4	4	762
3	Allergy	1	1	13
4	Hepatology	1	1	82
5	Pathology	1	1	82

Jeanne‐Marie Devaster

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial Isabel Leroux‐Roels, Astrid Borkowski, Thomas Vanwolleghem, The Lancet VaccinationCross-protectionVaccine DevelopmentAntigen SparingImmunology	2007	500
Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness Ann R. Falsey, Janet E. McElhaney, Gerrit A. van Essen, The Journal of Infectious Diseases	2014	284
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations David Mayhew, Nathalie Devos, Christophe Lambert, Thorax	2018	267
A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD Tom Wilkinson, Emmanuel Aris, Simon Bourne, Thorax	2017	189
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial François Roman, Tejaswini Vaman, Beatrice Gerlach, Vaccine VaccinationVaccine SafetyCross-protectionRandomised TrialPreliminary Report	2009	167
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial Janet E. McElhaney, Jeanne‐Marie Devaster, Meral Esen, The Lancet Infectious Diseases VaccinationVaccine SafetyCross-protectionVaccinologyElderly People	2013	161
Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort Viktoriya L. Kim, Ngaire Coombs, Karl J. Staples, European Respiratory Journal	2017	84
Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis Olivier Le Moine, Jacques Devière, Jeanne‐Marie Devaster, Journal of Hepatology InflammationCytokineHepatologyAutoimmune DiseaseLiver Physiology	1994	82
Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example Veronika Wertzova, K Honegr, Eva Kaliskova, BMC Infectious Diseases	2009	81
Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults Mathieu Peeters, Walthère Dewé, Jolana Raupachová, BMC Infectious Diseases	2013	66

Page 1